- •Antiganglioside antibodies have been suggested to be associated with Guillain-Barre Syndrome (GBS).
- •Positivity rates for GQ1b and GM-1 were reduced during the SARS-CoV-2 pandemic, while GD1a and GD1b remained unchanged.
- •Certain forms of GBS may have been reduced due to mitigation strategies used during the SARS-CoV-2 pandemic.
Reports suggested an association between SARS-CoV-2 infection and GBS, but subsequent studies produced conflicting results regarding the incidence of GBS during the pandemic. This study assessed positivity rates for GQ1b, GM-1, GD1a, and GD1b for tests performed January 2016, through March 2021, at a national laboratory. Relative to pre-pandemic levels, positivity rates during the pandemic declined by 61% for GQ1b and 24% for GM-1, while unchanged for GD1a and GD1b. These findings suggest heterogeneity with positivity rates of GBS-associated ganglioside antibodies during the COVID-19 pandemic. Mitigation strategies during the pandemic may have reduced the frequency of certain forms of GBS.
Abbreviations:GBS (Guillain-Barré Syndrome)
Many neuroimmunologic disorders are thought to result after a prior viral or bacterial infection. Various mechanisms have been proposed to trigger these presumed autoimmune disorders from molecular mimicry to bystander activation (
Wanleenuwat et al., 2019). With the occurrence of the COVID-19 pandemic, case reports have suggested a temporal association between COVID-19 and some neuroimmunologic disorders, including disorders such as inflammatory antiganglioside neuropathies.
- Wanleenuwat P.
- Iwanowski P.
- Kozubski W.
Antiganglioside antibodies in neurological diseases.
J. Neurol. Sci. 2019; 408116576
One such neuroimmunologic disorder is Guillain-Barré syndrome (GBS), which includes acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN). There are clear infectious triggers for GBS, including viral infections such as Epstein Barr virus, Zika virus, Haemophilus influenzae and bacterial infections such as Campylobacter jejuni (
Koike and Katsuno, 2021). Several case reports have suggested a temporal association with SARS-CoV-2 infection and the subsequent occurrence of GBS (Table 1). This led to several epidemiologic studies to examine if the incidence of GBS increased during the COVID-19 pandemic. While several studies suggested an increase in GBS during the pandemic (
- Koike H.
- Katsuno M.
Emerging infectious diseases, vaccines and Guillain-Barré syndrome.
Clin. Exp. Neuroimmunol.. 2021; https://doi.org/10.1111/cen3.12644
Fragiel et al., 2021;
- Fragiel M.
- Miro O.
- Llorens P.
- et al.
Incidence, clinical, risk factors and outcomes of Guillain-Barre in COVID-19.
Ann. Neurol. 2021; 89: 598-603
Abu-Rumeileh et al., 2021;
- Abu-Rumeileh S.
- Abdelhak A.
- Foschi M.
- Tumani H.
- Otto M.
Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.
J. Neurol. 2021; 268: 1133-1170
Filosto et al., 2021), a study from the United Kingdom found a reduction in the number of cases despite using a number of techniques to determine whether there was an association between COVID-19 and GBS (
- Filosto M.
- Cotti Piccinelli S.
- Gazzina S.
- et al.
Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions.
J. Neurol. Neurosurg. Psychiatry. 2021; 92: 751-756
Keddie et al., 2021). In particular, cases of COVID-19 and GBS in various regions did not appear to correlate and the authors concluded there was no epidemiologic evidence that SARS-CoV-2 was causative of GBS (
- Keddie S.
- Pakpoor J.
- Mousele C.
- et al.
Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome.
Brain. 2021; 144: 682-693
Keddie et al., 2021). However, in these studies GBS was viewed as a homogenous disorder. Interestingly, over 50% of GBS cases have identifiable antibodies present to various gangliosides (
- Keddie S.
- Pakpoor J.
- Mousele C.
- et al.
Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome.
Brain. 2021; 144: 682-693
Cutillo et al., 2020), making it possible to examine whether the COVID-19 pandemic affected the different forms of GBS in a heterogeneous fashion.
- Cutillo G.
- Saariaho A.-H.
- Meri S.
Physiology of gangliosides and the role of antiganglioside antibodies in human diseases.
Cell. Mol. Immunol. 2020; 17: 313-322
Table 1Antibody positive cases of Guillain-Barre syndrome or Miller-Fisher syndrome.
|Author||N||Time course||Neurological symptoms||GBS specific antibody||Comments|
Guilmot et al., 2021
Immune-mediated neurological syndromes in SARS-CoV-2-infected patients.
J. Neurol. 2021; 2021: 751-757
|3||Neurological symptoms developed 5–21 days after COVID-19 symptoms||One patient each developed cranial neuropathy and meningo-polyradiculitis, brainstem encephalitis, and delirium with associated involuntary movements and ataxia||Anti-GD1b IgG||Questionable pathogenicity of anti-GD1b due to highly variable clinical presentations. Also identified a case of anti-Caspr2 encephalitis.|
Masuccio et al., 2021
A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.
J. Neurol. 2021; 268: 2327-2330
|1||Neurological symptoms developed 15 days after COVID-19 symptoms||Quadriparesis, decreased tactile and pain sensations in lower extremities, urinary retention, perineal areflexia, DTR increased in all limbs. Electrophysiology was indicative of acute motor axonal neuropathy and MRI showed hyperintense lesions in the spinal cord at T2||Anti-GD1b IgM||Rare case of both myelitis and GBS with antibody positivity. COVID-19 nasal swab was negative, but COVID-19 antibodies were found in the blood.|
Gutiérrez-Ortiz et al., 2020
Miller fisher syndrome and polyneuritis cranialis in COVID-19.
Neurology. 2020; 95: e601-e605
|2||Neurological symptoms developed 3–5 days after COVID symptoms||Patient one had anosmia, ageusia, right internuclear ophthalmoparesis, right fascicular oculomotor palsy, ataxia. Patient two had areflexia, ageusia, bilateral abducens palsy.||Patient one was positive for Anti-GD1b IgG, patient two negative||Miller-Fisher syndrome was probable in one patient and polyneuritis cranialis was likely in the other.|
Dufour et al., 2021
GM1 ganglioside antibody and COVID-19 related Guillain Barre syndrome - a case report, systemic review and implication for vaccine development.
Brain Behav. Immun. Health. 2021; 12100203
|1||Neurological symptoms developed 21 days after positive COVID test||Ascending areflexic paralysis of lower extremities, absent DTR, ageusia, anosmia, MRI negative for demyelination.||Positive for Anti-GM1, anti-GD1a, anti-GD1b, anti-GQ1b||Resolution of symptoms was achieved with IVIG, but no neurophysiological studies were performed.|
Kopscik et al., 2020
A case report of acute motor and sensory polyneuropathy as the presenting symptom of SARS-CoV-2.
Clin. Pract. Cases Emerg. Med. 2020; 4: 352-354
|1||Neurological symptoms started 2 months before positive COVID test||Progressive weakness, numbness, difficulty walking, cranial nerve abnormalities, dysmetria, ataxia, and absent lower extremity reflexes.||Anti-GQ1b IgG positive||Patient did not have typical COVID-19 symptoms such as fever or respiratory involvement. Neurological symptoms developed before positive test for COVID-19|
Lantos et al., 2020
COVID-19-associated miller fisher syndrome: MRI findings.
Am. J. Neuroradiol. 2020; 41: 1184-1186
|1||Neurological symptoms started 2 days after COVID-19 symptoms developed||Reduced sensation and paresthesia in lower limbs, left eye drooping, blurry vision, enlargement of left cranial nerve 3 on MRI||Anti-GM1 IgG was in the equivocal range, all others negative||MFS was diagnosed, despite negative autoantibodies, due to consistent symptomatology with MFS.|
Gigli et al., 2021
Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?.
J. Neurol. 2021; 268: 1195-1197
|8||Unclear time course||Paresthesias, tetraparesis in multiple patients||1 patient positive for anti-GD1a IgG and anti-GT1b IgG, 5 negative, 2 not tested||While these patients may have GBS, the association seems questionable based on the unclear time course and lack of positive COVID-19 tests|
Chan et al., 2021
A case series of Guillain-Barré Syndrome After COVID-19 infection in New York.
Neurol. Clin. Pract. 2021; 11: e576-e578
|2||Neurological symptoms developed 18–23 days after onset of COVID-19 symptoms||Patient one had paresthesias, gait disturbance, facial weakness, dysarthria, dysphagia, CSF results consistent with GBS. Patient two had paresthesias, gait disturbance, absent reflexes in the legs, facial weakness, autonomic dysfunction, respiratory failure.||Patient one was not tested, patient two was positive for anti-GM2 IgG/IgM||Electromyography was deferred in both patients due to infection control measures.|
Lowery et al., 2020
Atypical variant of Guillain Barre syndrome in a patient with COVID-19.
J. Crit. Care Med. 2020; 6: 231-236
|1||Neurological symptoms developed 14 days after onset of COVID-19 symptoms||Gait ataxia, left facial and bilateral lower extremity weakness, dysphagia, quadriparesis, global areflexia, cranial nerve 3, 4, and 6 weakness.||Positive for Anti-GQ1b IgG||MFS with GBS overlap was diagnosed.|
Petrelli et al., 2020
Acute motor axonal neuropathy related to COVID-19 infection: a new diagnostic overview.
J. Clin. Neuromuscul. Dis. 2020; 22: 120-121
|1||Neurological symptoms developed 17 days after onset of COVID-19 symptoms||Hypoesthenia, loss of mobility, upper limb flaccid paralysis, DTR absent on right side, electroneurography had absence of a demyelinating pattern, but showed axonal-only motor neuropathy||Positive for anti-GM1 IgG and anti-GD1a IgG||GBS diagnosed based on presence of autoantibodies and symptomatology.|
Civardi et al., 2020
Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection.
J. Neurol. Neurosurg. Psychiatry. 2020; 91: 1361-1362
|1||Neurological symptoms developed 10 days after onset of COVID-19 symptoms||Lower limb weakness, paresthesias, generalized areflexia, nerve conduction studies showed demyelinating pattern. Eventually developed quadriplegia and neuromuscular respiratory failure||Positive for anti-GM1 IgG, anti-GD1b IgG, anti-GD1a IgG||GBS diagnosed based on presence of autoantibodies and symptomatology.|
N = number of patients in study.
In this study, we examined the occurrence of four ganglioside antibodies associated with GBS based on testing at a US reference clinical laboratory. Our goal was to assess changes in the incidence of these GBS-associated antibodies during the COVID-19 pandemic compared to pre-pandemic testing.
2. Materials and methods
All testing was performed by Quest Diagnostics. Detection of anti-GQ1B, anti-GM1, anti-GD1a, and anti-GD1b antibodies was performed using covalent ELISA technology tests developed and validated by Quest Diagnostics.
2.1 Study population
All GQ1b, GM1, GD1a, and GD1b, results from tests performed January 1, 2016 through March 31, 2021 that included a company-wide unique identifier were selected for potential inclusion in this study. The study population for each test result was limited to one result per patient; if any test detected antibodies, that patient was classified as positive. If antibodies were detected multiple times for the same patient, the earliest detection date was used to assess cohort trends in positivity over time. If the same patient was negative multiple times, the first negative date was used to assess cohort trends in positivity over time. Patients with indeterminate results were excluded as their status could not be classified.
Patients were assessed geographically by United States Health and Human Services (HHS) Region. When patient state data were not available, the ordering clinician's account state was used. The “pandemic” period was defined as the period from April 1, 2020, through March 31, 2021 to align with quarterly analysis.
2.3 Statistical analyses
Differences in proportions between groups were analyzed using the chi-square test. Trends in positivity rates among age groups were analyzed using the Cochran-Armitage test for trend. HHS region 9 (California, Arizona, Hawaii, Nevada) was used as the reference group in statistical analysis because it had the most patients. Multivariable logistic regression models were performed to assess the impact on positivity of potential changes in the demographic factors of patients tested for each antibody during the pandemic. The model used a stepwise entry criterion of p < 0.05 and excluded patients with missing values for any included factor. Data analyses were performed using SAS® Studio 3.6 on SAS® 9.4 (SAS Institute Inc., Cary, NC, USA). This Quest Diagnostics Health Trends® study was deemed exempt by the WCG Institutional Review Board (Puyallup, Washington).
The potential cohort included 25,010 patients with GQ1b results, 45,051 patients with GM1 results, 19,711 patients with GD1a results, and 18,962 patients with GD1b results. A small number of patients were excluded due to having only indeterminate/inconclusive results (4 for GQ1b, 3 for GM1, 1 for GD1a, and 3 for GD1b), leaving a final analytic cohort representing over 99.9% of potential patients for each outcome (Table 2).
Table 2Demographics of patient testing and positivity for GBS-associated antiganglioside antibodies.
|Total||25,006||660 (2.6)||45,048||7734 (17.2)||19,711||1390 (7.1)||18,959||556 (2.9)|
|Female||12,557||266 (2.1)*||21,191||3683 (17.4)||9921||586 (5.9)*||9748||251 (2.6)||**|
|Male (ref)||12,434||394 (3.2)||23,824||4050 (17.0)||9779||804 (8.2)||9197||305 (3.3)|
|Age Group (years)|
|<18 y||532||23 (4.3)*||418||60 (14.4)||218||8 (3.7)**||183||3 (1.6)|
|18–29 y||1422||67 (4.7)*||1868||235 (12.6)*||910||48 (5.3)*||831||24 (2.9)|
|30–49 y||5008||172 (3.4)*||7893||1337 (16.9)||3717||237 (6.4)*||3513||78 (2.2)|
|50–69 y||10,498||271 (2.6)*||19,581||3401 (17.4)||8391||589 (7.0)||8205||276 (3.4)|
|≥70 y (ref)||7538||127 (1.7)||15,273||2700 (17.7)||6469||508 (7.9)||6220||175 (2.8)|
|Neurology||9427||103 (1.1)*||19,214||3287 (17.1)||8673||609 (7.0)||8957||241 (2.7)|
|Hospital||6565||305 (4.7)*||11,220||1925 (17.2)||4404||368 (8.4)*||3967||152 (3.8)||*|
|General Practice||2151||39 (1.8)*||3317||586 (17.7)||1611||104 (6.5)||1556||46 (3.0)|
|Internal Medicine||952||12 (1.3)*||2958||495 (16.7)||1092||71 (6.5)||950||29 (3.1)|
|All Others (ref)||5864||200 (3.4)||8119||1414 (17.4)||3857||235 (6.1)||3497||87 (2.5)|
|Health and Human Services Region|
|1: CT, MA, ME, NH, RI, VT||1609||55 (3.4)*||3270||594 (18.2)||1601||115 (7.2)||1070||37 (3.5)|
|2: NJ, NY||3060||60 (2.0)||6878||1117 (16.2)||2833||213 (7.5)||2206||54 (2.5)|
|3: DE, DC, MD, PA, VA, WV||2247||90 (4.0)*||3879||606 (15.6)||1381||95 (6.9)||1415||40 (2.8)|
|4: AL, FL, GA, KY, MS, NC, SC, TN||5857||128 (2.2)||9324||1576 (16.9)||3978||293 (7.4)||4615||132 (2.9)|
|5: IL, IN, MI, MN, OH, WI||2597||88 (3.4)*||2917||585 (20.1)*||1306||92 (7.0)||1664||61 (3.7)|
|6: AR, LA, NM, OK, TX||1785||55 (3.1)**||3789||630 (16.6)||1584||122 (7.7)||1144||36 (3.2)|
|7: IA, KS, MO, NE||726||9 (1.2)||1042||269 (25.8)*||802||53 (6.6)||599||19 (3.2)|
|8: CO, MT, ND, SD, UT, WY||261||14 (5.4)*||342||39 (11.4)*||100||4 (4.0)||84||1 (1.2)|
|9: AZ, CA, HI, NV (ref)||6067||135 (2.2)||12,301||2059 (16.7)||5276||338 (6.4)||5761||163 (2.8)|
|10: AK, OR, ID, WA||581||13 (2.2)||1215||249 (20.5)*||825||62 (7.5)||388||13 (3.4)|
Chi-square test p < 0.05**; p < 0.01.
Patient demographics and their respective associations with positive outcomes are shown in Table 2. Notable findings included a significantly higher proportion of males compared to females testing positive for GQ1b (p < 0.001), GD1a (p < 0.001), and GD1b (p = 0.010). GQ1b positivity rate decreased with increasing age groups (p < 0.001 for trend). Conversely, there was a statistically significant increase in the GM1 and GD1a positivity rates with increasing age groups (p < 0.001 for trend). The GQ1b positivity rate was highest in hospital inpatients (4.7%, 95% CI 4.1–5.2%) and lowest in neurology outpatients (1.1%, 95% CI 0.9–1.3%). We also examined the top ICD-10 diagnosis codes included on the requisition for both tests ordered and positive results (see Supplementary Table 1). The top diagnosis code associated with all of the antibodies ordered was polyneuropathy, followed by hereditary and idiopathic neuropathy and paresthesia of the skin. Because ICD10 diagnosis codes for Miller Fisher syndrome and acute ataxic neuropathy do not exist, more general diagnoses were associated with the anti-ganglioside antibodies associated with those disorders. Vitamin D deficiency was also a frequently listed ICD-10 code for all of the anti-ganglioside tests ordered.
Quarterly trends in patients tested and positivity are shown in Fig. 1, Fig. 2. In general, testing volume was substantially reduced during the second quarter of 2020 (approximately 20% for most tests), consistent with the shutdown that occurred as a result of the pandemic. In subsequent quarters, testing generally increased, suggesting that testing for antibodies associated with neuroimmunologic disorders had returned to pre-pandemic levels or greater. The GQ1b positivity rate demonstrated a significant 61% decline during the pandemic period compared to the preceding period studied (1.2%, 95% CI 0.9–1.4%; versus 3.1%, 95% CI 2.9–3.4%, p < 0.001; Fig. 1A). In a logistic regression model adjusting for all demographic factors presented in Table 2, the GQ1b positivity rate was significantly lower during the pandemic period (AOR 0.33, 95% CI 0.26–0.43).
The GM1 positivity rate demonstrated a significant 19% decline during the pandemic period compared to the prior year (13.8%, 95% CI 13.2–14.5%; versus 17.0%, 95% CI 16.3–17.8%, p < 0.01; Fig. 1B). A logistic model adjusting for demographic factors confirmed this association (AOR 0.78, 95% CI 0.72–0.85) GM1 positivity rates also declined significantly in each of the prior two years; however, it is notable that the positivity rate in Q1 2021 (11.4%, 95% CI 10.3–12.6%) was the lowest rate during the study period.
Although it did drop substantially in the most recent quarter where data was available, the GD1a positivity rate was not significantly lower during the pandemic compared to the entire pre-pandemic period (6.5%, 95% CI 5.8–7.2%; versus 7.2%, 95% CI 6.8–7.6%, p = 0.109; Fig. 2A). The GD1b positivity rate was not lower during the pandemic compared to the prior year (1.8%, 95% CI 1.4–2.2%; versus 1.9%, 95% CI 1.5–2.4%, p = 0.559; Fig. 2B). Logistic regression models adjusting for demographic factors confirmed the lack of association.
In this study, we examined the positivity rates for several ganglioside antibodies that had been shown to be temporally associated with SARS-CoV-2 infection in case reports (see Table 1). Specifically, we examined whether positivity for antibodies associated with GBS changed during the COVID-19 pandemic. This area is controversial in the literature. Some studies suggest an association between COVID-19 infection and GBS, while a larger study published by Keddie et al. utilizing a number of methodologies did not show an association and actually reported a decrease in cases of GBS in the United Kingdom. Studies on GBS are fraught with issues regarding case definition and ascertainment bias (
Sevjar et al., 2011). We examined positivity rates for antibodies associated with various forms of GBS and found that GQ1b positivity rates declined dramatically after the onset of the pandemic. GM1 positivity rates also declined significantly during the pandemic, but this may reflect a continuation of a declining trend that was demonstrated prior to the pandemic. These findings may suggest, as others have concluded, that while COVID-19 may be able to trigger neuroimmunologic conditions such as GBS, that mitigation strategies such as social distancing, mask wearing, and hand hygiene could reduce exposure to infectious agents that might otherwise trigger some forms of GBS, particularly that associated with GQ1b.
- Sevjar J.J.
- Baughman A.L.
- Wise M.
- Morgan O.W.
Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis.
Neuroepidemiology. 2011; 36: 123-133
One limitation of this study is that we could not determine the specific temporal association of COVID-19 exposure with positivity for ganglioside antibodies. This was partly because SARS-CoV-2 seropositivity is several fold higher than molecular testing positivity, mostly because of the large number of asymptomatic infections occurring in the general population (
Rogawski et al., 2021;
- Rogawski E.T.
- Guertin K.A.
- Becker L.
- et al.
Assessment of seroprevalence of SARS-CoV-2 and risk factors associated with COVID-19 infection among outpatients in Virginia.
JAMA Netw. Open. 2021; 4e2035234
Stefanelli et al., 2021). Thus, we only compared the positivity rate of antiganglioside antibodies during the pandemic to pre-pandemic levels. In addition, some of the variation in test positivity may represent seasonal variation known to occur with GBS (
- Stefanelli P.
- Bella A.
- Fedele G.
- et al.
Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with high incidence of COVID-19 cases: a population-based study.
Clin. Microbiol. Infect. 2021; 27: 633.e1-633.e7
Webb et al., 2015).
- Webb A.J.S.
- Brain S.A.E.
- Wood R.
- Rinaldi S.
- Turner M.R.
Seasonal variation in Guillain-Barre syndrome: a systematic review, meta-analysis, and Oxfordshire cohort study.
J. Neurol. Neurosurg. Psychiatry. 2015; 86: 1196-1201
As the exact reason for testing was unknown, there is potential selection bias. However, we were able to view the top 30 ICD-10 codes associated with the ordering of anti-ganglioside testing and this information for the top 10 codes is provided in Supplementary Table 1. Because Quest Diagnostics does not perform all GBS-associated antibody testing in the country, these data should be interpreted as a large, but not exhaustive sample of national data. In fact, this study is one of the largest to date assessing neuroimmunological complications during the COVID-19 pandemic. However, we were not able to review patient charts for specific symptoms of Guillain-Barré to determine reliability of ICD-10 diagnosis codes. In addition, our estimates may be conservative; not every case of GBS demonstrates antibody positivity. Moreover, some clinicians do not order antibody testing even if they suspect GBS. However, the frequency of vitamin D deficiency may reflect the known association of low vitamin D levels observed in GBS and CIDP (
Elf et al., 2014). Notably, as vaccines became available for SARS-CoV-2, reports began to surface of GBS in association with vaccination (
- Elf K.
- Askmark H.
- Nygren I.
- Punga A.R.
Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies.
J. Neurol. Sci. 2014; 345: 184-188
Allen et al., 2021;
- Allen C.M.
- Ransamy S.
- Tarr A.W.
- et al.
Guillain-Barre variant occurring after SARS-CoV-2 vaccination.
Ann. Neurol. 2021; 90: 315-318
Maramattom et al., 2021). One study of 702 patients known to have GBS then vaccinated for SARS-CoV-2 found only one patient required short-term medical care for recurring symptoms (
- Maramattom B.V.
- Krishnan P.
- Paul R.
- et al.
Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine.
Ann. Neurol. 2021; 90: 312-314
Shapiro Ben David et al., 2021). For this reason, we specifically examined the positivity rates for ganglioside antibodies prior to the time when vaccines became available to the general public.
- Shapiro Ben David S.
- Potasman I.
- Rahamim-Cohen D.
Rate of recurrent Guillain-Barré syndrome after mRNA COVID-19 vaccine BNT162b2.
JAMA Neurol. 2021; 78: 1409-1411https://doi.org/10.1001/jamaneurol.2021.3287
These data suggest that heterogeneity in terms of the effect that the COVID-19 pandemic has had on rates of GBS associated with ganglioside antibodies. In particular, while positivity rates for GD1a and GD1b remained largely unchanged during the pandemic, rates of positivity for GQ1b and GM1 were significantly reduced during the pandemic. While these findings do not exclude the possibility that immune responses to SARS-CoV-2 may trigger autoimmune responses to gangliosides as suggested in several case reports (see Table 1), they do suggest that mitigation strategies taken during the pandemic could possibly have reduced the frequency of certain forms of GBS, such as those mediated by GQ1b and GM1.
The following are the supplementary data related to this article.
- Supplementary Table 1
ICD-10 Codes Associated with Anti-ganglioside Testing.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
MKR, JKN, RAL, and HWK are employees of Quest Diagnostics and MKR and HWK own stock in Quest Diagnostics.
- Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.J. Neurol. 2021; 268: 1133-1170
- Guillain-Barre variant occurring after SARS-CoV-2 vaccination.Ann. Neurol. 2021; 90: 315-318
- A case series of Guillain-Barré Syndrome After COVID-19 infection in New York.Neurol. Clin. Pract. 2021; 11: e576-e578
- Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection.J. Neurol. Neurosurg. Psychiatry. 2020; 91: 1361-1362
- Physiology of gangliosides and the role of antiganglioside antibodies in human diseases.Cell. Mol. Immunol. 2020; 17: 313-322
- GM1 ganglioside antibody and COVID-19 related Guillain Barre syndrome - a case report, systemic review and implication for vaccine development.Brain Behav. Immun. Health. 2021; 12100203
- Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies.J. Neurol. Sci. 2014; 345: 184-188
- Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions.J. Neurol. Neurosurg. Psychiatry. 2021; 92: 751-756
- Incidence, clinical, risk factors and outcomes of Guillain-Barre in COVID-19.Ann. Neurol. 2021; 89: 598-603
- Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?.J. Neurol. 2021; 268: 1195-1197
- Immune-mediated neurological syndromes in SARS-CoV-2-infected patients.J. Neurol. 2021; 2021: 751-757
- Miller fisher syndrome and polyneuritis cranialis in COVID-19.Neurology. 2020; 95: e601-e605
- Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome.Brain. 2021; 144: 682-693
- Emerging infectious diseases, vaccines and Guillain-Barré syndrome.Clin. Exp. Neuroimmunol.. 2021; https://doi.org/10.1111/cen3.12644
- A case report of acute motor and sensory polyneuropathy as the presenting symptom of SARS-CoV-2.Clin. Pract. Cases Emerg. Med. 2020; 4: 352-354
- COVID-19-associated miller fisher syndrome: MRI findings.Am. J. Neuroradiol. 2020; 41: 1184-1186
- Atypical variant of Guillain Barre syndrome in a patient with COVID-19.J. Crit. Care Med. 2020; 6: 231-236
- Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine.Ann. Neurol. 2021; 90: 312-314
- A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.J. Neurol. 2021; 268: 2327-2330
- Acute motor axonal neuropathy related to COVID-19 infection: a new diagnostic overview.J. Clin. Neuromuscul. Dis. 2020; 22: 120-121
- Assessment of seroprevalence of SARS-CoV-2 and risk factors associated with COVID-19 infection among outpatients in Virginia.JAMA Netw. Open. 2021; 4e2035234
- Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis.Neuroepidemiology. 2011; 36: 123-133
- Rate of recurrent Guillain-Barré syndrome after mRNA COVID-19 vaccine BNT162b2.JAMA Neurol. 2021; 78: 1409-1411https://doi.org/10.1001/jamaneurol.2021.3287
- Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with high incidence of COVID-19 cases: a population-based study.Clin. Microbiol. Infect. 2021; 27: 633.e1-633.e7
- Antiganglioside antibodies in neurological diseases.J. Neurol. Sci. 2019; 408116576
- Seasonal variation in Guillain-Barre syndrome: a systematic review, meta-analysis, and Oxfordshire cohort study.J. Neurol. Neurosurg. Psychiatry. 2015; 86: 1196-1201
Published online: April 21, 2022
Accepted: April 19, 2022
Received in revised form: April 7, 2022
Received: January 19, 2022
© 2022 The Authors. Published by Elsevier B.V.
User licenseCreative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
How you can reuse
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy